

Thank you for your email of January 9, 2024 informing us of the minor revision of our manuscript. We also appreciate the time and effort you and each of the reviewers have dedicated to providing insightful feedback on ways to strengthen our paper. Thus, it is with great pleasure that we submit the revised for further consideration. We have incorporated changes that reflect the detailed suggestions the reviewers have graciously provided. We also hope that our revisions and the responses satisfactorily address all the issues and concerns the reviewers have noted. The suggested changes within the manuscript are denoted by highlights [yellow]. Summarized comments below are italicized, and followed by our replies.

Thank you very much for your consideration regarding this manuscript.

Reviewer #1

Specific Comments to Authors:

1. In the discussion part, this paper briefly discussed the progress of neoadjuvant therapy for MMT, and only 1 of the 11 reference articles cited was published after 2020. Please add the references published in recent years, and add the research progress on the latest treatment of MMT or MPNSTs in the discussion part, and briefly introduce the changes of their molecular mechanisms.

Response: We appreciate the reviewer's comment. Following the reviewer's comments, we added four papers published since 2020 to the References. And we tried to include the latest opinions on treatment and molecular mechanisms in the Discussion.

2. Figure2 The pictures of pathological tissue sections are not clear enough and the number is small, can you add more clear pictures?

Response: High-magnification H&E staining (x300) was added to Figure 2, and Immune-histochemical examination of S-100 and desmin staining at high magnification (x300) was added to Figure 3.